- Report
- April 2024
Global
From €300EUR$332USD£267GBP
- Report
- September 2022
- 30 Pages
Global
From €2659EUR$2,750USD£2,284GBP
- Report
- August 2022
- 161 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- August 2022
- 30 Pages
Global
From €2659EUR$2,750USD£2,284GBP
- Report
- August 2022
- 30 Pages
Global
From €3142EUR$3,250USD£2,699GBP
- Report
- November 2021
- 101 Pages
Global
From €4351EUR$4,500USD£3,737GBP
- Report
- June 2021
- 50 Pages
China
From €2514EUR$2,600USD£2,159GBP
- Drug Pipelines
- February 2018
- 19 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Drug Pipelines
- February 2018
- 39 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- February 2018
- 19 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Drug Pipelines
- June 2021
- 95 Pages
Global
From €1934EUR$2,000USD£1,661GBP
Xolair (omalizumab) is a biologic drug used to treat moderate to severe allergic asthma and chronic idiopathic urticaria (hives). It is a monoclonal antibody that binds to immunoglobulin E (IgE), a type of antibody that plays a role in allergic reactions. Xolair works by blocking IgE from binding to mast cells, which are responsible for releasing histamine and other chemicals that cause allergic reactions. Xolair is administered as an injection every two to four weeks.
Xolair is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2003. It is currently the only biologic drug approved for the treatment of allergic asthma and chronic idiopathic urticaria. Xolair is marketed by Genentech, a subsidiary of Roche, and Novartis. Other companies involved in the Xolair market include GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more
